{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:40:07Z","timestamp":1790872807838,"version":"4.1.0"},"reference-count":52,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,12,11]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>T cell engaging therapies, like chimeric antigen receptor T cells and T cell bispecific antibodies (TCBs), efficiently redirect T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing, a process that is accompanied by the release of cytokines. Despite their promising efficacy in the clinic, treatment with TCBs is associated with a risk of cytokine release syndrome (CRS). The aim of this study was to identify small molecules able to mitigate cytokine release while retaining T cell-mediated tumor killing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>By screening a library of 52 Food and Drug Administration approved kinase inhibitors for their impact on T cell proliferation and cytokine release after CD3 stimulation, we identified mTOR, JAK and Src kinases inhibitors as potential candidates to modulate TCB-mediated cytokine release at pharmacologically active doses. Using an in vitro model of target cell killing by human peripheral blood mononuclear cells, we assessed the effects of mTOR, JAK and Src kinase inhibitors combined with 2+1\u2009T cell bispecific antibodies (TCBs) including CEA-TCB and CD19-TCB on T cell activation, proliferation and target cell killing measured by flow cytometry and cytokine release measured by Luminex. The combination of mTOR, JAK and Src kinase inhibitors together with CD19-TCB was evaluated in vivo in non-tumor bearing stem cell humanized NSG mice in terms of B cell depletion and in a lymphoma patient-derived xenograft (PDX) model in humanized NSG mice in terms of antitumor efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The effect of Src inhibitors differed from those of mTOR and JAK inhibitors with the suppression of CD19-TCB-induced tumor cell lysis in vitro, whereas mTOR and JAK inhibitors primarily affected TCB-mediated cytokine release. Importantly, we confirmed in vivo that Src, JAK and mTOR inhibitors strongly reduced CD19-TCB-induced cytokine release. In humanized NSG mice, continuous treatment with a Src inhibitor prevented CD19-TCB-mediated B cell depletion in contrast to mTOR and JAK inhibitors, which retained CD19-TCB efficacy. Ultimately, transient treatment with Src, mTOR and JAK inhibitors minimally interfered with antitumor efficacy in a lymphoma PDX model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Taken together, these data support further evaluation of the use of Src, JAK and mTOR inhibitors as prophylactic treatment to prevent occurrence of CRS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003766","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T10:21:27Z","timestamp":1642760487000},"page":"e003766","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0576-0546","authenticated-orcid":false,"given":"Gabrielle","family":"Leclercq","sequence":"first","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"},{"name":"Department of Pharmaceutical Sciences, Division Molecular and Systems Toxicology, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Haegel","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Toso","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Green","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Sam","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Pulko","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliese","family":"Schneider","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Giusti","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Challier","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Freimoser-Grundschober","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Larivi\u00e8re","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-2712","authenticated-orcid":false,"given":"Alex","family":"Odermatt","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Division Molecular and Systems Toxicology, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stern","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Umana","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bacac","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"2025100313433385000_10.1.e003766.1","doi-asserted-by":"crossref","unstructured":"Goebeler M-E , Bargou RC . T cell-engaging therapies \u2014 BiTEs and beyond. Nat Rev Clin Oncol 2020.","DOI":"10.1038\/s41571-020-0347-5"},{"key":"2025100313433385000_10.1.e003766.2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"2025100313433385000_10.1.e003766.3","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-21-0073","article-title":"Targeting solid tumors using CD3 bispecific antibodies","volume":"20","author":"Crawford","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025100313433385000_10.1.e003766.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1696"},{"key":"2025100313433385000_10.1.e003766.5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1203498","article-title":"CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors","volume":"5","author":"Bacac","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100313433385000_10.1.e003766.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"2025100313433385000_10.1.e003766.7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100313433385000_10.1.e003766.8","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"2025100313433385000_10.1.e003766.9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-med-062617-035821","article-title":"Redirected T cell cytotoxicity in cancer therapy","volume":"70","author":"Clynes","year":"2019","journal-title":"Annu Rev Med"},{"key":"2025100313433385000_10.1.e003766.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2018.10.026"},{"key":"2025100313433385000_10.1.e003766.11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025100313433385000_10.1.e003766.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.227"},{"key":"2025100313433385000_10.1.e003766.13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2025100313433385000_10.1.e003766.14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"2025100313433385000_10.1.e003766.15","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzw040"},{"key":"2025100313433385000_10.1.e003766.16","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2725"},{"key":"2025100313433385000_10.1.e003766.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"2025100313433385000_10.1.e003766.18","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"2025100313433385000_10.1.e003766.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2025100313433385000_10.1.e003766.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901401"},{"key":"2025100313433385000_10.1.e003766.21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8434"},{"key":"2025100313433385000_10.1.e003766.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"2025100313433385000_10.1.e003766.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2025100313433385000_10.1.e003766.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100313433385000_10.1.e003766.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"2025100313433385000_10.1.e003766.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100313433385000_10.1.e003766.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"2025100313433385000_10.1.e003766.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.02.006"},{"key":"2025100313433385000_10.1.e003766.29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood.2020005655","article-title":"Concomitant use of a dual Src\/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL","volume":"137","author":"Leonard","year":"2021","journal-title":"Blood"},{"key":"2025100313433385000_10.1.e003766.30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"2025100313433385000_10.1.e003766.31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"2025100313433385000_10.1.e003766.32","article-title":"653\u2005Dasatinib as a rapid pharmacological ON\/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release","volume":"8","author":"Leclercq","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313433385000_10.1.e003766.33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002582"},{"key":"2025100313433385000_10.1.e003766.34","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"2025100313433385000_10.1.e003766.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1739"},{"key":"2025100313433385000_10.1.e003766.36","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"2025100313433385000_10.1.e003766.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025100313433385000_10.1.e003766.38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4875.4875","article-title":"Low dose steroids can alleviate blinatumomab-associated toxicities without negatively impacting treatment efficacy","volume":"126","author":"Mori","year":"2015","journal-title":"Blood"},{"key":"2025100313433385000_10.1.e003766.39","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"2025100313433385000_10.1.e003766.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"2025100313433385000_10.1.e003766.41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650295","article-title":"Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of Hyperinflammation syndrome","volume":"12","author":"Huarte","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025100313433385000_10.1.e003766.42","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.bbmt.2016.12.003","article-title":"Ruxolitinib prevents cytokine release syndrome after car T-cell therapy without impairing the anti-tumor effect in a xenograft model","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"2025100313433385000_10.1.e003766.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1271"},{"key":"2025100313433385000_10.1.e003766.44","first-page":"19","article-title":"Prophylactic ruxolitinib for cytokine release syndrome (CRS) in relapse\/refractory (R\/R) AML patients treated with flotetuzumab","volume":"136","author":"GL","year":"2020","journal-title":"Blood"},{"key":"2025100313433385000_10.1.e003766.45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.12.436","article-title":"Trial in progress: a phase 2, single-arm, open-label study of Itacitinib (ITA) for the prevention of chimeric antigen receptor (CAR) T-Cell\u2013Induced cytokine release syndrome (CRS)","volume":"26","author":"Park","year":"2020","journal-title":"Biology Blood Marrow Transplant"},{"key":"2025100313433385000_10.1.e003766.46","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100313433385000_10.1.e003766.47","first-page":"11","article-title":"Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers","volume":"7","author":"Thudium","year":"2015","journal-title":"Clin Pharmacol"},{"key":"2025100313433385000_10.1.e003766.48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112391","article-title":"Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors","volume":"199","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"2025100313433385000_10.1.e003766.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"2025100313433385000_10.1.e003766.50","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389469"},{"key":"2025100313433385000_10.1.e003766.51","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.10.009"},{"key":"2025100313433385000_10.1.e003766.52","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:43:46Z","timestamp":1759524226000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003766"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003766","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}